UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.792

Sortiert nach

Half‐life extended factor VIII for the treatment of hemophilia A

Journal of thrombosis and haemostasis, 2015-06, Vol.13 (S1), p.S176-S179

Tiede, A.

2015

Link zum Volltext

Verfügbarkeit prüfen

Thromboembolic Risks of Non-Factor Replacement Therapies in Hemophilia

Hamostaseologie, 2017-01, Vol.37 (4), p.307

Tiede, A

2017

Link zum Volltext

Verfügbarkeit prüfen

Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A

Journal of thrombosis and haemostasis, 2013-04, Vol.11 (4), p.670-678

2013

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH‐AH 01/2010 study

Journal of thrombosis and haemostasis, 2016-05, Vol.14 (5), p.940-947

2016

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single‐centre cohort study

Journal of thrombosis and haemostasis, 2008-04, Vol.6 (4), p.569-576

2008

Link zum Volltext

Verfügbarkeit prüfen

PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-09, Vol.23 (5), p.697-704

2017

Link zum Volltext

Verfügbarkeit prüfen

QUANTITATIVE PHARMACOKINETIC MODEL TO CHARACTERIZE AND EXTRAPOLATE LONG-TERM FVIII ACTIVITY LEVELS IN PATIENTS WITH SEVERE HEMOPHILIA A TREATED WITH VALACTOCOGENE ROXAPARVOVEC

Hematology, Transfusion and Cell Therapy, 2023-10, Vol.45, p.S451

2023

Link zum Volltext

Verfügbarkeit prüfen

Prophylaxis vs. on-demand treatment with Nuwiq® (Human-cl rhFVIII) in adults with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-05, Vol.22 (3), p.374-380

2016

Link zum Volltext

Verfügbarkeit prüfen

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-09, Vol.19 (5), p.691-697

2013

Link zum Volltext

Verfügbarkeit prüfen

Anti‐FcγRIIB (CD32) Antibodies Differentially Modulate Murine FVIII‐Specific Recall Response in vitro

Scandinavian journal of immunology, 2017-08, Vol.86 (2), p.91-99

2017

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of a novel extended half‐life glycoPEGylated factor IX, nonacog beta pegol (N9‐GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-07, Vol.23 (4), p.547-555

2017

Link zum Volltext

Verfügbarkeit prüfen

Management of acquired haemophilia A

Hamostaseologie, 2015, Vol.35 (4), p.311

2015

Link zum Volltext

Verfügbarkeit prüfen

A Comprehensive Analysis of the Cellular and EBV‐Specific MicroRNAome in Primary CNS PTLD Identifies Different Patterns Among EBV‐Associated Tumors

American journal of transplantation, 2014-11, Vol.14 (11), p.2577-2587

2014

Link zum Volltext

Verfügbarkeit prüfen

The first recombinant FVIII produced in human cells - an update on its clinical development programme

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-01, Vol.20 (s1), p.1-9

2014

Link zum Volltext

Verfügbarkeit prüfen

siRNA Mediated Knockdown of Tissue Factor Expression in Pigs for Xenotransplantation

American journal of transplantation, 2015-05, Vol.15 (5), p.1407-1414

2015

Link zum Volltext

Verfügbarkeit prüfen

Turoctocog alfa (recombinant factor VIII). Manufacturing, characteristics and clinical trial results

Hämostaseologie, 2015, Vol.35 (4), p.364

2015

Link zum Volltext

Verfügbarkeit prüfen

Co‐morbidities and bleeding in elderly patients with haemophilia—A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH)

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-09, Vol.23 (5), p.721-727

2017

Link zum Volltext

Verfügbarkeit prüfen

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-11, Vol.17 (6), p.854-859

2011

Link zum Volltext

Verfügbarkeit prüfen

Pain therapy in haemophilia in Germany. Patient survey (BESTH study)

Hämostaseologie, 2015, Vol.35 (2), p.167

2015

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-11, Vol.20 (s7), p.1-11

2014

Link zum Volltext

Verfügbarkeit prüfen

Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-09, Vol.22 (5), p.e445-e449

2016

Link zum Volltext

Verfügbarkeit prüfen

Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-01, Vol.21 Suppl 1 (s1), p.1-12

2015

Link zum Volltext

Verfügbarkeit prüfen

Risk of bleeding and haemorrhagic complication with rivaroxaban--periprocedural management of haemostasis

Hämostaseologie, 2012, Vol.32 (4), p.287

2012

Link zum Volltext

Verfügbarkeit prüfen

Increased amounts of von Willebrand factor are bound to microparticles after infusion of desmopressin

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-03, Vol.19 (2), p.236-241

2013

Link zum Volltext

Verfügbarkeit prüfen

Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fcγ receptor II (CD32)

Annals of the rheumatic diseases, 2008-02, Vol.67 (2), p.154-161

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.792

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.477)
Mit Volltextzugriff
(1.600)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(857)
Life Sciences & Biomedicine
(537)
Humans
(378)
Physical Sciences
(280)
Technology
(191)
Female
(182)
Male
(178)
Biological And Medical Sciences
(128)
Chemistry
(124)
Social Sciences
(123)
Adult
(113)
Hematology
(111)
Middle Aged
(110)
Animals
(104)
Aged
(81)
Biochemistry & Molecular Biology
(76)
Medical Sciences
(75)
Remote Sensing
(75)
Physics
(64)
Fundamental And Applied Biological Sciences. Psychology
(60)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(722)
Ingenta
(541)
MEDLINE
(503)
Single Journals
(324)
Journals@Ovid
(320)
Wiley Online Library - AutoHoldings Journals
(314)
Elsevier ScienceDirect Journals Complete
(239)
IngentaConnect Journals
(234)
Wiley Online Library
(223)
EZB-NALI5-00465 Elsevier Archive NL
(179)
JSTOR
(113)
Springer Journals
(104)
American Institute of Physics (AIP) Journals
(97)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(71)
IEEE Xplore
(65)
Taylor & Francis Journals Auto-Holdings Collection
(62)
Taylor & Francis
(54)
Taylor & Francis Online
(51)
Ebook Central Perpetual and DDA
(49)
Oxford journals
(46)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Half‐life extended factor VIII for the treatment of hemophilia A

Thromboembolic Risks of Non-Factor Replacement Therapies in Hemophilia

Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A

Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH‐AH 01/2010 study

Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single‐centre cohort study

PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A

QUANTITATIVE PHARMACOKINETIC MODEL TO CHARACTERIZE AND EXTRAPOLATE LONG-TERM FVIII ACTIVITY LEVELS IN PATIENTS WITH SEVERE HEMOPHILIA A TREATED WITH VALACTOCOGENE ROXAPARVOVEC

Prophylaxis vs. on-demand treatment with Nuwiq® (Human-cl rhFVIII) in adults with severe haemophilia A

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy

Anti‐FcγRIIB (CD32) Antibodies Differentially Modulate Murine FVIII‐Specific Recall Response in vitro

Pharmacokinetics of a novel extended half‐life glycoPEGylated factor IX, nonacog beta pegol (N9‐GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials

Management of acquired haemophilia A

A Comprehensive Analysis of the Cellular and EBV‐Specific MicroRNAome in Primary CNS PTLD Identifies Different Patterns Among EBV‐Associated Tumors

The first recombinant FVIII produced in human cells - an update on its clinical development programme

siRNA Mediated Knockdown of Tissue Factor Expression in Pigs for Xenotransplantation

Turoctocog alfa (recombinant factor VIII). Manufacturing, characteristics and clinical trial results

Co‐morbidities and bleeding in elderly patients with haemophilia—A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH)

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A

Pain therapy in haemophilia in Germany. Patient survey (BESTH study)

Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?

Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A

Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014

Risk of bleeding and haemorrhagic complication with rivaroxaban--periprocedural management of haemostasis

Increased amounts of von Willebrand factor are bound to microparticles after infusion of desmopressin

Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fcγ receptor II (CD32)

Suchergebnisse filtern